Hussman Strategic Advisors, Inc. Krystal Biotech, Inc. Transaction History
Hussman Strategic Advisors, Inc.
- $320 Million
- Q4 2024
A detailed history of Hussman Strategic Advisors, Inc. transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Hussman Strategic Advisors, Inc. holds 4,200 shares of KRYS stock, worth $650,454. This represents 0.21% of its overall portfolio holdings.
Number of Shares
4,200Holding current value
$650,454% of portfolio
0.21%Shares
1 transactions
Others Institutions Holding KRYS
# of Institutions
307Shares Held
24.4MCall Options Held
483KPut Options Held
364K-
Black Rock Inc. New York, NY3.95MShares$611 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.85MShares$441 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.62MShares$406 Million7.18% of portfolio
-
State Street Corp Boston, MA1.45MShares$225 Million0.01% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA988KShares$153 Million9.67% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $3.97B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...